← Leaderboards
Jerry L. Nadler
University Of Virginia Charlottesville
$10,120,845
Attributed
$14,018,390
Total exposure
15
Grants
6
Lead (contact PI)
Attributed= this PI's even-split share of every grant they're on (the fair, additive number). Exposure = full size of all those grants.
Funding over time
peak $2.8M · FY2005–25$5M$3.8M$2.5M$1.3M$0
'05
'06
'07
'08
'09
'10
'11
'12
'13
'14
'15
'16
'17
'18
'19
'20
'21
'22
'23
'24
'25
Funding mix
By agency
NIH$25,768,979 · 15
VA$0 · 1
By mechanism
P01$14,188,244 · 5
R01$7,713,913 · 5
UC4$2,401,653 · 1
P30$738,951 · 1
R21$555,000 · 1
M01$171,218 · 2
Top collaborators
- Raghavendra G Mirmira6 shared
- Elena V Galkina5 shared
- Decio Laks Eizirik1 shared
- Thomas O Metz1 shared
- Carmella Evans Molina1 shared
Most similar at University Of Virginia Charlottesville
Same institution · by research overlap
- Raghavendra G Mirmira$22,841,626
- David L Hill$11,750,076
- Margaret A Shupnik$7,555,831
- Coleen A McNamara$22,811,214
- Rama Natarajan$30,287,552
Others in their field
Top investigators on “Diabetes Mellitus”
- Jeffrey P Krischer · University Of South Florida$608,226,434
- Kathryn Hirst · Caritas St. Elizabeth'S Medical Center$177,347,135
- John M Lachin · George Washington University$155,262,668
- David M Nathan · Massachusetts Institute Of Technology$142,806,023
- Judith S Hochman · New York University School Of Medicine$100,149,457
- Jose A Luchsinger · Columbia University Health Sciences$75,551,718
Research focus
Diabetes MellitusAtherosclerosisPathway InteractionsInflammatoryPreventLeadSignal TransductionInsulinHyperglycemiaMacrophageImmuneCytokineInsulin ResistanceIn VivoInflammationCellsPlayPhenotypeDiabeticCardiovascular DiseasesMonocyteMouse ModelDietBlood Vessels
Grant awards (59)
Development of 12-Lipoxygenase Inhibitors for diabetes treatment.$0
I21 · FY2025 · VA · contact PI
Impact of atherosclerosis, metabolic syndrome, and STAT4-dependent immunity on Alzheimer's disease$402,764
R01 · FY2021 · HL
Myeloid cell-specific role of STAT4 in atherosclerosis and metabolic dysfunction$363,320
R01 · FY2021 · HL
Myeloid cell-specific role of STAT4 in atherosclerosis and metabolic dysfunction$436,607
R01 · FY2020 · HL
Myeloid cell-specific role of STAT4 in atherosclerosis and metabolic dysfunction$443,404
R01 · FY2019 · HL
Myeloid cell-specific role of STAT4 in atherosclerosis and metabolic dysfunction$458,235
R01 · FY2018 · HL
Validation of small molecule 12-lipoxygenase inhibitors in metabolic disease$412,855
R01 · FY2018 · DK
Validation of small molecule 12-lipoxygenase inhibitors in metabolic disease$54,055
R01 · FY2018 · DK
Validation of small molecule 12-lipoxygenase inhibitors in metabolic disease$448,740
R01 · FY2017 · DK
Validation of small molecule 12-lipoxygenase inhibitors in metabolic disease$451,139
R01 · FY2016 · DK
Role of the Interleukin12/STAT4 Pathway in Insulin Resistance and Atherosclerosis$399,642
R01 · FY2016 · HL · contact PI
Validation of small molecule 12-lipoxygenase inhibitors in metabolic disease$481,326
R01 · FY2015 · DK
Role of the Interleukin12/STAT4 Pathway in Insulin Resistance and Atherosclerosis$404,047
R01 · FY2015 · HL · contact PI
Biomarkers Of Beta Cell Stress In Type 1 Diabetes (BetaMarker)$2,401,653
UC4 · FY2014 · DK
Role of the Interleukin12/STAT4 Pathway in Insulin Resistance and Atherosclerosis$401,996
R01 · FY2014 · HL · contact PI
Role of the Interleukin12/STAT4 Pathway in Insulin Resistance and Atherosclerosis$348,670
R01 · FY2013 · HL · contact PI
Role of the Interleukin12/STAT4 Pathway in Insulin Resistance and Atherosclerosis$43,950
R01 · FY2013 · HL · contact PI
Role of the Interleukin12/STAT4 Pathway in Insulin Resistance and Atherosclerosis$366,250
R01 · FY2012 · HL · contact PI
Role of Inflammation in Vascular Disease in the Metabolic Syndrome and Diabetes$249,466
P01 · FY2010 · HL · contact PI
GLUCOSE, INSULIN IN DIABETIC VASCULAR DISEASE$98,669
P01 · FY2010 · HL · contact PI
Lipid Mediators in Pancreatic Islet Dysfunction$31,672
R01 · FY2010 · DK · contact PI
Role of Inflammation in Vascular Disease in the Metabolic Syndrome and Diabetes$271,791
P01 · FY2009 · HL · contact PI
GLUCOSE, INSULIN IN DIABETIC VASCULAR DISEASE$107,201
P01 · FY2009 · HL · contact PI
Role of Inflammation in Vascular Disease in the Metabolic Syndrome and Diabetes$260,559
P01 · FY2008 · HL · contact PI
GLUCOSE, INSULIN IN DIABETIC VASCULAR DISEASE$102,484
P01 · FY2008 · HL · contact PI
Role of Inflammation in Vascular Disease in the Metabolic Syndrome and Diabetes$314,481
P01 · FY2007 · HL · contact PI
Lipid Mediators in Pancreatic Islet Dysfunction$153,257
R01 · FY2007 · DK · contact PI
Lipid Mediators in Pancreatic Islet Dysfunction$132,396
R01 · FY2007 · DK · contact PI
GLUCOSE, INSULIN IN DIABETIC VASCULAR DISEASE$67,343
P01 · FY2007 · HL · contact PI
Glucose, Insulin in Diabetic Vascular Disease$1,744,203
P01 · FY2006 · HL · contact PI
Lipid Mediators in Pancreatic Islet Dysfunction$305,279
R01 · FY2006 · DK · contact PI
Role of Inflammation in Vascular Disease in the Metaboli$260,848
P01 · FY2006 · HL · contact PI
CORE--CELL AND ISLET ISOLATION CORE$177,587
P30 · FY2006 · DK · contact PI
GLUCOSE, INSULIN IN DIABETIC VASCULAR DISEASE$102,197
P01 · FY2006 · HL · contact PI
Glucose, Insulin in Diabetic Vascular Disease$2,019,412
P01 · FY2005 · HL
Lipid Mediators in Pancreatic Islet Dysfunction$312,198
R01 · FY2005 · DK
CORE--CELL AND ISLET ISOLATION CORE$177,587
P30 · FY2005 · DK
Glucose, Insulin in Diabetic Vascular Disease$1,962,709
P01 · FY2004 · HL
Lipid Mediators in Pancreatic Islet Dysfunction$311,600
R01 · FY2004 · DK
CORE--CELL AND ISLET ISOLATION CORE$177,587
P30 · FY2004 · DK
Monocyte Function in Diabetes$15,454
M01 · FY2004 · RR
Glucose, Insulin in Diabetic Vascular Disease$1,907,646
P01 · FY2003 · HL
New Antiinflammatory Agents to Prevent Damage to Islets$277,500
R21 · FY2003 · DK
CORE--CELL AND ISLET ISOLATION CORE$206,190
P30 · FY2003 · DK
Glucose, Insulin in Diabetic Vascular Disease$1,853,169
P01 · FY2002 · HL
New Antiinflammatory Agents to Prevent Damage to Islets$277,500
R21 · FY2002 · DK
Lipoxygenase and vascular disease in diabetes$183,722
P01 · FY2002 · HL
Core--Swine model$0
P01 · FY2002 · HL
GENETIC RELATIONSHIPS BETWEEN NIDDM &ATHEROSCLEROSIS IN HISPANIC POPULATION$0
M01 · FY2002 · RR
Glucose, Insulin in Diabetic Vascular Disease$1,741,713
P01 · FY2001 · HL
Lipoxygenase and vascular disease in diabetes$183,722
P01 · FY2001 · HL
GENETIC RELATIONSHIPS BETWEEN NIDDM &ATHEROSCLEROSIS IN HISPANIC POPULATION$155,764
M01 · FY2001 · RR
Core--Swine model$0
P01 · FY2001 · HL
GENETIC RELATIONSHIPS BETWEEN NIDDM &ATHEROSCLEROSIS IN HISPANIC POPULATION$0
M01 · FY2001 · RR
GLUCOSE/INSULIN IN DIABETIC VASCULAR DISEASE$521,737
P01 · FY2000 · HL
LIPID MEDIATORS IN INDUCED PANCREATIC ISLET DYSFUNCTION$376,943
R01 · FY2000 · DK
CALCIUM AND LIPOXYGENASE AND ALDOSTERONE REGULATION$173,568
R01 · FY2000 · DK
CORE-LIPID/ASSAY$117,586
P01 · FY2000 · HL
ROLE OF LIPOXYGENASES IN ATHEROGENESIS IN DIABETES MELLITUS$117,586
P01 · FY2000 · HL